A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.

To assess quality of life, patients will complete questionnaires at four time points.